Kraig Biocraft Laboratories Increases R&D Capacity

Kraig Biocraft Laboratories, Inc., a leader in spider silk technology, announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas.

The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deployment of new advanced equipment. These improvements have roughly tripled screening throughput, allowing the R&D team to keep up with the rapid development of new transgenics.

Kraig Labs implemented these upgrades in direct response to the rapid technical progress made under Project Atlas. Atlas is the Company’s next-generation recombinant spider silk program focused on creating advanced biomaterials with potential industrial and defense applications.

The recently commissioned equipment streamlines the screening of newly created transgenic lines and the analysis of their resulting spider silk expression levels. Project Atlas is now generating significant numbers of transgenics and potential candidates for new production materials. This expanded screening capacity was needed to keep pace with the rate of new transgenic creation, which is now at the highest levels in the Company’s history. By automating portions of the testing workflow, Kraig Labs can now rapidly process and evaluate significantly more samples, quickly identifying new, exciting transgenics.

In addition to the increased screening capacity, Kraig Labs also strengthened its analytical testing capabilities. These tools provide deeper insight into the expression levels and functional impact of each engineered transgenic line. This enhanced visibility allows the research team to identify the most promising genetic designs and prioritize them for advancement into the Company’s production pipeline.

“With the pace of discovery we are seeing in Project Atlas, it became clear that we needed to expand our screening and analysis capacity to keep up with the speed of innovation,” said Kim Thompson, Founder and CEO of Kraig Labs. “This investment in staff and technology further strengthens our position as a leader in advanced biomaterials. We believe we have a wide lead on our competitors, and it is the goal of this investment to expand that lead further.”

Dr. Zhang, the Company’s Chief Scientist, emphasized the impact these upgrades will have on the research pipeline.

“Project Atlas involves the creation and evaluation of numerous complex genetic constructs designed to work together to produce highly specialized silk proteins,” said Dr. Zhang. “The expansion of our testing infrastructure dramatically increases our testing capacity to match the increased pace of transgenic creation. We can now analyze many more transgenic lines in parallel and better quantify how each genetic insert is performing. This level of screening power is essential for isolating the highest-performing lines and rapidly advancing them into production.”

By significantly increasing screening capacity and analytical insight, Kraig Labs expects to shorten development timelines and improve its ability to identify breakthrough material candidates.